Related Experiment Video
Updated: Dec 25, 2025
05:23
Investigating Migraine-Like Behavior Using Light Aversion in Mice
Published on: August 11, 2021
4.3K
CGRP antagonists for decreasing migraine frequency: New options, long overdue
Julia Bucklan1,2, Zubair Ahmed3,4
1Center for General Neurology, Department of Neurology, Cleveland Clinic bucklaj@ccf.org.
Cleveland Clinic Journal of Medicine
|April 3, 2020
Summary
New monoclonal antibody drugs targeting calcitonin gene-related peptide (CGRP) offer a novel approach to preventing debilitating migraine attacks. These targeted therapies represent a significant advancement over traditional medications repurposed for migraine management.
Area of Science:
- Neurology
- Pharmacology
Background:
- Traditional migraine preventive treatments often involve repurposed drugs for epilepsy, depression, or hypertension.
- These older medications may have off-target effects and varying efficacy in migraine management.
Purpose of the Study:
- To introduce novel therapeutic agents for migraine prevention.
- To highlight the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology.
Main Methods:
- Review of emerging migraine preventive therapies.
- Focus on monoclonal antibodies targeting CGRP or its receptors.
Main Results:
- Erenumab, galcanezumab, fremanezumab, and eptinezumab are new monoclonal antibodies for migraine prevention.
- These drugs specifically target the CGRP pathway, a key factor in migraine.
Conclusions:
- Monoclonal antibodies targeting CGRP represent a new class of migraine-specific preventive treatments.
- These targeted therapies offer a promising alternative to repurposed medications for migraine management.
Related Concept Videos
01:28Drugs Acting on Autonomic Ganglia: Blockers
1.5K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.5K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
458
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
458
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
523
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
523
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.2K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
809
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
809
01:26Cholinergic Antagonists: Therapeutic Uses
1.3K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.3K